Name (Synonyms) | Correlation | |
---|---|---|
drug830 | Daily placebo Wiki | 1.00 |
drug456 | Bolus placebo Wiki | 1.00 |
drug1345 | IC14 Wiki | 1.00 |
drug829 | Daily Vitamin D3 Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
There is one clinical trial.
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receive a multivitamin containing vitamin D.
Description: metabolite of vitamin D
Measure: Change in total circulating 25(OH)D concentration Time: monthly in COVID-19 negative participants through study completion for 1 yearDescription: metabolite of vitamin D
Measure: Change in total circulating 25(OH)D concentration in COVID-19 positives Time: baseline, 2 and 4 weeks, then months 3, 6, 9 and 12 in COVID-19 positive participantsDescription: The presence or absent of SARS-CoV-2 antibody will be measured at baseline, 3, 6, 9 and 12 months.
Measure: Change in SARS-CoV-2 antibody titers Time: every 3 months up to 12 monthsDescription: At baseline, 3, 6, 9 and 12 months, inflammatory cytokines will be measured in participant plasma samples. Cytokines to be measured are Interferon-gamma (IFN-g), Interleukin-1beta (IL-1B), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and Tumor Necrosis Factor-alpha (TNFa). Values of these cytokines at baseline will compared to those at 3, 6, 9, and 12 months
Measure: Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha Time: baseline and every 3 months up to 12 monthsDescription: COVID-19 positive participants or if COVID-19 negatives develop respiratory symptoms will complete this respiratory survey daily for 2 weeks
Measure: Respiratory symptoms Time: daily for 2 weeksDescription: Inventory of signs and symptoms of rhino/sinusitis. These signs include sneezing, running nose, cough, dizziness, fatigue, and sense of smell. Each sign is rated on a scale of 0 to 5, with 0 indicating not problem, for instance 1 indicating mild problem, 4 indicating severe problem and 5 indicating problem as bad as it can be.
Measure: Signs and symptoms of rhino/sinusitis Time: Baseline then 3, 6, 9 and 12 months in negatives and daily for 2 weeks in positivesDescription: Dietary intake assessment
Measure: NCI Dietary Intake Time: baseline then at 6 and 12 monthsDescription: Survey of participant health problems
Measure: Charlson Comorbidity survey Time: baseline then at 6 and 12 monthsDescription: Assessment of physical activity of each participant
Measure: Paffenberger Physical Activity Assessment Time: Baseline then at 6 and 12 monthsDescription: Each participant will complete the Perceived Stress Scale Questionnaire (PSS) to assess their perceived stress. Assessments are base on a scale of 0 to 4, with 0 indicating "never" and 4 indicating "very often"
Measure: Perceived stress Time: monthly for 1 yearDescription: Each participant will complete the and Pandemic Stress Index Questionnaire (PSI) to assess their perceived stress cause by the pandemic. Assessments are base on a scale of 0 to 6, with 0 indicating "not at all" and 5 indicating "extremely," and 6 indicating "decline to answer."
Measure: Pandemic stress Time: monthly for 1 yearDescription: Personality characteristics of each participant
Measure: NEO-Personality Inventory Time: baseline visitDescription: A health assessment will be completed by each participant monthly for 1year. This health. This is for information on health status only and not for comparative assessment.
Measure: GrassrootsHealth Monthly Health assessment Time: baseline, 6, and 12 months